Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib and Bortezomib for Eliminating HLA Antibodies in Platelet Transfusion Refractoriness
NCT07635511Phase 3Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jun 2026
- Primary completion
- Jan 2029
01
Overview
A Phase 3 trial of acalabrutinib tablet (Variant 1), bortezomib in platelet transfusion refractoriness (PTR), sponsored by First Affiliated Hospital of Soochow University. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)bortezomib
03
Conditions
platelet transfusion refractoriness (PTR)
Beyond the preview
Go deeper on NCT07635511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07635511.